Cell permeable inhibitors of the scaffold protein plenty of SH3 domains (POSH) or Sh3Rfl
AssigneeThe Curators of the University of Missouri
InventorMark A. Daniels
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Curators of the University of Missouri
InventorMark A. Daniels
Estimating the term…
Here, we identify Plenty of SH3 (POSH) and JNK-interacting protein 1 (JIP-1) as a multi-protein scaffold network for TCR-mediated JNK1 activation in CD8+ T-cells. Disruption of the POSH/JIP-1 complex led to profound defects in the activation of JNK1, as well as deficient activation or induction of the transcription factors c-Jun, T-bet and Eomesodermin. Furthermore, disruption of the POSH/JIP complex in CD8+ T-cells resulted in impaired proliferation, decreased cytokine expression and the inability to control tumors. Collectively, these data identify a mechanism for the specific regulation of TCR-dependent JNK1 activation and function that is key for CD8+ T-cell responses. A group of compounds are described that individually or in concert target a common set of biological pathways important in T cell function, activation of innate inflammation, ischemic reperfusion injury, HIV release and oncogenesis.
A composition comprising at least one chimeric peptide, wherein the at least one chimeric peptide comprises:
A chimeric peptide comprising a peptide sequence for inhibiting and disrupting POSH scaffold networks and a protein transduction domain, wherein the peptide sequence comprises the amino acid sequence selected from the group consisting of:
Dependencies are inferred from the claim text.